Navigation Links
K94 Discoveries, Inc. Announces Seed Financing To Advance Targeted Drug Conjugates To Treat Pancreatic And Other Cancers

BATON ROUGE, La., Sept. 24, 2013 /PRNewswire/ -- K94 Discoveries, Inc., (K94) a new biotechnology company applying hormone receptor-targeting technology to develop novel cancer therapies, today announced that it has closed a $300,000 seed financing. The financing was provided by BVM Capital, LLC, through its Themelios Ventures II, LP fund.  Ross P. Barrett, Managing Partner of BVM Capital, is interim President of the new company.

K94 Discoveries is developing cancer therapies based on proprietary hormone receptor-targeting discoveries by scientific founder William Hansel, Ph.D., a Professor at the William Hansel Cancer Prevention laboratory at the Pennington Biomedical Research Center of Louisiana State University (LSU). Dr. Hansel found that the luteinizing hormone-releasing hormone (LHRH) receptors present in large numbers on the surface of a wide variety of cancer cells can be harnessed to target cancer drugs.  A version of this technology is also embodied in the targeted cancer drugs being developed by Esperance Pharmaceuticals, a clinical-stage company partly based on Dr. Hansel's inventions

K94 researchers are using a similar approach to develop targeted drug conjugates by combining LHRH with the naturally-occurring plant extract curcumin, which has attracted interest as a potential anticancer agent for decades.  Preclinical studies indicate that curcumin exhibits multiple anticancer properties, and in laboratory tests it promotes cancer cell death and slows the growth of tumors.  However, curcumin's therapeutic potential has been limited by its poor solubility, which the company's novel drug conjugates are designed to overcome.  K94 is initially focusing on pancreatic cancer and is also conducting research in ovarian and breast cancer.

"We are fortunate in Louisiana to have access to extraordinary scientists such as Dr. Hansel, who think 'outside the box' in devising new ways to combat cancer," commented Mr. Barrett.  "Early data suggest that combining his pioneering work in hormone receptor-targeting therapies with novel anticancer agents could be a promising approach, and we welcome the opportunity to help advance this technology to the next stage."

Pennington's William Hansel Cancer Prevention research unit was established in 2005 to honor Dr. Hansel's contributions to the field.  Cancer researchers at LSU's Feist Weiller Cancer Center in Shreveport are also conducting research for K94 Discoveries.

Dr. Hansel noted, "The name K94 is in honor of the men of Company K of the 94th Division in General Patton's Third Army, which I commanded in World War II.  Their willingness to take on big challenges and confront daunting risks inspire me to persevere in the fight against cancer.  I have long been intrigued by the anticancer potential of certain naturally-occurring compounds such as curcumin, and look forward to assessing its cancer-fighting potential in combination with the powerful hormone receptor-targeting technology we discovered here at LSU."

Toxicology testing on the company's lead compounds is expected to commence soon, with human clinical trials targeted for 2015.

About K94 Discoveries, Inc.
K94 Discoveries is a biotechnology company developing novel targeted anticancer drugs based on discoveries by scientists at LSU's Pennington Biomedical Research Center and research at the Feist Weiller Cancer Center. The company's initial product is a drug conjugate that combines the naturally-occurring anticancer substance curcumin with luteinizing hormone-releasing hormone (LHRH) that targets the hormone receptors present in large numbers on the surface of cancer cells.

About BVM Capital LLC
BVM Capital LLC is a Southeast-based venture capital firm that provides equity capital to early and expansion stage companies with proprietary technology platforms or unique products addressing large markets. The partners of BVM Capital manage assets of more than $40 million allocated to three funds: generalist fund Louisiana Ventures, LP and Themelios Ventures I and II LP, which are focused on life science and healthcare opportunities across the Southeast.  For more information, visit Contacts:

MediaK94 Discoveries

BLL PartnersRoss Barrett

BarbaraLindheim(318) 746-8430


SOURCE K94 Discoveries, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... Cardiac Pacemaker Market Outlook to 2019 - Rise in Cardiac ... " report to their offering. ... Boston scientific and others. --> ... Medtronic, Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
Breaking Medicine Technology:
(Date:11/27/2015)... Francisco, California (PRWEB) , ... November 27, 2015 , ... ... Janis Joplin Ann Arbor Michigan boxing style concert posters. This is one of Joplin's ... at the Canterbury House at the University of Michigan in Ann Arbor. The According ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... substance abuse located in central Michigan, have come together on Thanksgiving Day to ... produced video, available for viewing on the Serenity Point YouTube channel, patients displayed ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... a real-time eReferral system for diagnostic imaging in the Waterloo region. Using the ... and Nuclear Medicine tests directly from their electronic medical record (EMR) without the ...
(Date:11/26/2015)... ... , ... The Catalent Applied Drug Delivery Institute today announced ... form selection in early phase drug development. The first of these is to ... the UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating their record ... performed their 6,000th free flap breast reconstruction surgery! , “What an accomplishment for the ... to rebuild lives and it’s an honor to have served all of these women.” ...
Breaking Medicine News(10 mins):